Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV clinical programs — 62 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
Status
Public
HQ
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
Founded
2016
Employees
9
Programs
99
Drugs
26
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Lakefront Biotherapeutics NV projects

62 ClinicalTrials.gov programs sponsored by Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV has 62 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

62 programs

Clinical programs

Page 1 of 2

  1. 100 mg GLPG1205

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  2. 100 mg dose of [14C] GLPG0634

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  3. 200 mg GLPG0634 as capsules, fasted

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  4. 500 mg GLPG1837 as oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  5. Atorvastatin

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  6. Filgotinib

    Lakefront Biotherapeutics NV

    Bioavailability

    phase 1 small molecule completed

    1 trial

  7. GLPG0187

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  8. GLPG0187

    Lakefront Biotherapeutics NV

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  9. GLPG0187 prodrug

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  10. GLPG0259

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  11. GLPG0259 fumarate

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  12. GLPG0259 solution

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  13. GLPG0492

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

  14. GLPG0555

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  15. GLPG0555 solid dispersion

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  16. GLPG0634

    Lakefront Biotherapeutics NV

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  17. GLPG0634

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

  18. GLPG0634 100mg capsule once a day for 10 days

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  19. GLPG0634 50 mg

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  20. GLPG0778

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  21. GLPG0974

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  22. GLPG1205

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  23. GLPG1205 50mg q.d.

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  24. GLPG1205 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  25. GLPG1205 single ascending doses, oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  26. GLPG1690

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  27. GLPG1690 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  28. GLPG1690 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  29. GLPG1837 500 mg

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  30. GLPG1837 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  31. GLPG1972

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  32. GLPG1972 - A

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  33. GLPG1972 600 mg oral solution fasted

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  34. GLPG1972 cohort 1

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  35. GLPG1972 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  36. GLPG1972 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  37. GLPG2222 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  38. GLPG2451 dose regimen A

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  39. GLPG2451 multiple dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  40. GLPG2451 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  41. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  42. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  43. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  44. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  45. GLPG3121

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  46. GLPG3121 SAD

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  47. GLPG3312 IR

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  48. GLPG3667

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

Frequently asked questions

How many clinical projects does Lakefront Biotherapeutics NV have?

62 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.